December 02, 2016
By Reuters Staff
(Reuters) - The European Medicines Agency warned on Friday that some of the most successful hepatitis C treatments on the market could reactivate hepatitis B in patients.
The agency recommended that patients be screened to ensure they are not infected with both kinds of virus before being treated for hepatitis C.
The Pharmacovigilance Risk Assessment Committee's warning was against direct acting antivirals, which include Gilead Sciences Inc's Sovaldi (sofosbuvir), AbbVie Inc's Exviera (dasabuvir) and Viekirax (ombitasvir-paritaprevir-ritonavir), Johnson & Johnson's Olysio (simeprevir) and Bristol-Myers Squibb's Daklinza (daclatasvir).
(c) Copyright Thomson Reuters 2016. Click For Restrictions - http://about.reuters.com/fulllegal.asp